Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Andexanet alfa - Portola Pharmaceuticals

Drug Profile

Andexanet alfa - Portola Pharmaceuticals

Alternative Names: ALXN 2070; AndexXa; Coagulation factor Xa (recombinant), inactivated-zhzo; IndexXa; Ondexxya; PRT-064445; PRT-4445; PRT-44545; r-antidote; Recombinant factor-Xa-Portola; rfXa-inhibitor-antidote

Latest Information Update: 29 Jul 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Portola Pharmaceuticals
  • Developer Alexion AstraZeneca Rare Disease; Portola Pharmaceuticals
  • Class Antidotes; Antihaemorrhagics; Disulfides; Recombinant proteins
  • Mechanism of Action Blood coagulation stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemorrhage
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Haemorrhage

Most Recent Events

  • 21 Jul 2021 Alexion Pharmaceuticals has been acquired by AstraZeneca and changed its name to Alexion AstraZeneca Rare Disease
  • 15 May 2021 Updated efficacy and adverse event data from a phase IIIa/IV trial ANNEXA-4 in Haemorrhage presented at the 70th Annual Scientific Session of the American College of Cardiology (ACC-2021)
  • 12 Mar 2021 Alexion Pharmaceuticals plans to file NDA of andexanet alfa in Japan in the first quarter of 2021
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top